High-Grade Glioma
35
10
14
5
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
5 terminated out of 35 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (35)
APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)
Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
Concurrent Azeliragon With Craniospinal Irradiation
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma
Seizures During Radiotherapy for High-grade Gliomas
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
Surgical Suction Aspirates Fluorescence Measurement
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma